XOMA Royalty (XOMA) Current Deferred Revenue (2010 - 2026)
XOMA Royalty (XOMA) reported Current Deferred Revenue of $1.3 million for Q1 2026, down 5.77% on a YoY basis from $1.4 million in Q1 2025, and up 1.81% sequentially from $1.3 million in Q4 2025.
XOMA Royalty (XOMA) Current Deferred Revenue (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Current Deferred Revenue data on file, last reported at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue fell 5.77% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 5.77% YoY), and the FY2025 full-year result was $1.3 million, down 6.83% from the prior year.
- Current Deferred Revenue rose to $1.3 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $2.3 million in Q2 2024 to a low of $1.3 million in Q4 2025.
- A 5-year average of $1.8 million and a median of $1.8 million in 2022 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue rose 21.95% in 2023 and tumbled 37.65% in 2025, its largest moves.
- Tracing XOMA's Current Deferred Revenue over 5 years: stood at $1.9 million in 2022, then grew by 11.27% to $2.1 million in 2023, then plunged by 35.59% to $1.4 million in 2024, then dropped by 6.83% to $1.3 million in 2025, then climbed by 1.81% to $1.3 million in 2026.
- Business Quant data shows XOMA's Current Deferred Revenue at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.37 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 2.11 Mn |
| Sep 30, 2023 | 2.08 Mn |
| Jun 30, 2023 | 2.03 Mn |
| Mar 31, 2023 | 1.97 Mn |
| Dec 31, 2022 | 1.90 Mn |
| Sep 30, 2022 | 1.70 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.62 Mn |
| Dec 31, 2021 | 1.64 Mn |
| Sep 30, 2021 | 1.54 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Mar 31, 2021 | 1.48 Mn |